SeaStar Medical (ICU) announces that it has assumed all responsibility for direct sales, marketing and distribution of QUELIMMUNE to hospital customers. QUELIMMUNE is SeaStar Medical’s therapeutic device approved for the treatment of pediatric acute kidney injury, AKI, due to sepsis or a septic-like condition.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICU:
- SeaStar announces enrollment in NEURTALIZE-AKI trial passes halfway point
- SeaStar Medical announces presentation of new data on SCD at ASN 2024
- SeaStar expands NEUTRALIZE-AKI trial with two military medical facilities
- SeaStar Medical reports enrollment momentum in adult AKI trial
- SeaStar Medical eliminates all long-term debt